- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pharmacy Cost Trends Expected to Continue in the Double Digits
Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health.
Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health. The estimated specialty pharmacy drugs cost trends only are 22.7% in 2015, up from an 18.2% increase in 2014.
Upcoming specialty drugs are contributing to the dramatic spike in the cost trends, according to John Malley, leader of Aon Health’s Innovation Pharmacy Team. Specifically, he noted oncology drugs will be the largest category of specialty drug approvals in the near future and cholesterol drugs may also have a significant impact.
“Carriers continue to see price inflation as the single largest driver of increased medical costs, but an aging population, unhealthy lifestyle choices and provider consolidation are also contributing to the trend increase," Tim Nimmer, global chief actuary for Aon Health, said in a statement.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
